| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Autonomix Medical, Inc.$3.5
-0.04 (-1.14%)
Market Cap
4.55 M
EPS
-4.09
P/E Ratio
-
Value Trade
28.71 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
1.46 M
Operating CF
-3.07 M
Total Assets
7.60 M
Total Liabilities
1.71 M
Equity
5.89 M
D/E Ratio
12,345
25.27 %
Week
6.88 %
1 Month
8.37 %
3 Month
-57.1 %
6 Month
-99.74 %
5 Year
-99.74 %
All Time
Cash Data
Cash Position
7.00 M
Monthly Burn
1.02 M
Runway
5 mo
Burn Trend
StableSEC Filing
May 27, 2026
Overview
Volume
7.37 M
52 Week Range
0.20 - 2.64
% held by Insiders
7.59 %
% held by Institutions
4.22 %
Enterprise Value
-5.38 M
Total Shares
11.41 M
Short %
3.3 %
Float Shares
10.26 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-30 | First-in-class catheter-based sensing and ablation technology | Topline data readout | Topline data | — | – | – | – |
2024-09-30 | First-in-class catheter-based sensing and ablation technology | Topline data readout | Topline data | — | – | – | – |
2024-09-30 | First-in-class catheter-based sensing and ablation technology | Topline data readout | Topline data | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | pancreatic cancer | — | 2026-01-09 | consistent pain reduction regardless of disease severity | Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium Read More | |
— | pancreatic cancer | — | 2026-01-09 | consistent pain reduction regardless of disease severity | Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium Read More | |
— | pancreatic cancer | — | 2026-01-09 | consistent pain reduction regardless of disease severity | Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AMIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMIX▼ -1.1%today
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical has announced positive results from a preclinical study demonstrating its neural sensing platform's ability to detect and confirm changes in renal neural activity. The study showed that the platform could identify neural signals associated with nerve activity in the renal artery, supporting the development of physiology-guided renal denervation procedures. The findings suggest a significant advancement in providing real-time physiological feedback during treatment.
Read more →AMIX▼ -12.1%on this news
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Autonomix Medical has announced the issuance of U.S. Patent No. 12,471,776, enhancing its intellectual property for autonomic nervous system assessment technologies. This patent covers systems for monitoring physiologic signals, which may improve patient selection and treatment precision. The company aims to revolutionize nerve-targeted therapies, particularly for conditions like pancreatic cancer pain.
Read more →AMIXAutonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Autonomix Medical has been granted a U.S. patent for its innovative platform aimed at diagnosing and treating overactive bladder (OAB), a condition affecting 37 million Americans. The patent enhances the company's neural sensing technology and supports its strategy of organ-specific applications. The catheter-based system allows for precise nerve mapping and targeted therapy delivery, potentially improving treatment outcomes for patients with OAB.
Read more →AMIX▼ -9.7%on this news· ran to -23% by day 3shared move
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical has entered a warrant inducement agreement, allowing an investor to exercise outstanding warrants for approximately $2.6 million. The transaction involves the issuance of new warrants at a reduced exercise price, aimed at advancing the company's innovative nerve-targeted treatment technologies. The closing is expected by July 15, 2026, pending customary conditions.
Read more →AMIX▼ -12.5%on this news· ran to -25% by day 3shared move
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical has been granted a Canadian patent for its endoscopic sympathectomy systems, enhancing its intellectual property in the nerve-targeted therapy market. This patent supports the company's innovative approach to real-time nerve monitoring and diagnostic evaluation, aiming to improve treatment precision for chronic diseases. The company now holds 112 patents globally, reinforcing its leadership in the denervation market.
Read more →AMIXAutonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Autonomix Medical has announced a standalone neural sensing platform that can detect real-time renal nerve activity changes. This platform aims to enhance renal denervation procedures, potentially improving treatment outcomes for hypertension. The technology is designed for future applications across various nerve-targeted therapies, indicating a strategic expansion into the cardiovascular market.
Read more →AMIXAutonomix Announces Reverse Stock Split
Autonomix Medical, Inc. announced a 1-for-21 reverse stock split effective June 24, 2026. This move will consolidate approximately 11.4 million shares into around 543,000 shares, aimed at improving stock value. The company continues to develop innovative technologies for treating nervous system diseases, particularly focusing on pain management solutions.
Read more →AMIX▼ -6.5%on this news
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Autonomix Medical has released a new CEO Corner segment featuring CEO Brad Hauser, highlighting the company's growing recognition in the medical field. The segment discusses the acceptance of 13 abstracts at major conferences and the potential impact of their nerve-targeted treatment technology, particularly for pancreatic cancer pain. The company aims to revolutionize treatment through innovative nerve-sensing technology, although it remains investigational.
Read more →AMIXAutonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Autonomix Medical, Inc. showcased its clinical data at the Society of Surgical Oncology Annual Meeting, emphasizing its innovative approach to managing visceral cancer pain. Dr. Toufic Kachaamy discussed the potential impact of their technology, which aims to improve treatment outcomes for pancreatic cancer and other conditions. The presentation's selection for a podium slot underscores its relevance to the surgical oncology community.
Read more →AMIX▼ -10%on this news· ran to +27% by day 3
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Autonomix Medical, Inc. has been granted a U.S. patent for its innovative transvascular monitoring and treatment systems. This patent enhances the company's intellectual property portfolio, focusing on real-time validation of nerve-targeted treatments. The technology aims to improve procedural outcomes by enabling dynamic adjustments based on live feedback. It has potential applications across various clinical indications, including pain management.
Read more →AMIXAutonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Autonomix Medical has announced the acceptance of two abstracts for presentation at EuroPCR 2026, focusing on their nerve-targeting technology for pain mitigation in pancreatic cancer. The abstracts highlight the company's innovative approach to peripheral nerve modulation, reflecting increasing interest in their technology. CEO Brad Hauser emphasized the importance of participating in international forums to raise awareness of their platform's potential.
Read more →AMIX▼ -6.7%on this news
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Autonomix Medical has announced that its long-term data on pain mitigation in pancreatic cancer has been accepted for presentation at Digestive Disease Week 2026. The data focuses on the effectiveness of their transvascular radiofrequency energy-based ablation technique. This presentation aims to validate their approach within the gastroenterology community and highlight the potential benefits for patients suffering from severe pain.
Read more →AMIXAutonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
Autonomix Medical will present long-term clinical data on its transvascular RF ablation technology for pain mitigation in pancreatic cancer at ECIO 2026. The presentation, accepted for an oral session, aims to highlight the outcomes of this innovative approach. The technology targets relevant nerves to provide durable pain relief, addressing a significant unmet medical need.
Read more →AMIXAutonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
Autonomix Medical has announced that its abstract on pain mitigation in pancreatic adenocarcinoma has been selected for a Featured Abstract presentation at the SIR 2026 Annual Scientific Meeting. The study evaluates long-term outcomes of a novel transvascular RF energy-based ablation technique. The presentation will be delivered by Dr. Lindsay Machan, emphasizing the importance of addressing cancer-related pain.
Read more →AMIXAutonomix Medical to Present at LSI USA ’26
Autonomix Medical, Inc. has announced that CEO Brad Hauser will present at the LSI USA '26 conference, highlighting the company's advancements in precision nerve-targeted treatments. The event, taking place on March 17, 2026, will also provide opportunities for in-person meetings with investors. Autonomix's innovative technology aims to revolutionize diagnosis and treatment of nerve-related diseases, particularly focusing on pain management for pancreatic cancer. While promising, the technology remains investigational and has yet to receive marketing clearance in the U.S.
Read more →AMIXAutonomix Medical Selected for Best Innovation Competition at CRT 2026
Autonomix Medical has been selected to present at the Best Innovation Competition at CRT 2026, showcasing its innovative transvascular technology for nerve-targeted treatments. CEO Brad Hauser will deliver the presentation, emphasizing the technology's potential to enhance patient care by providing insights into peripheral nerve signaling. The selection underscores the company's commitment to advancing medical devices for nervous system diseases.
Read more →AMIXAutonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
Autonomix Medical, Inc. announced that its abstract on a novel RF-based technique for peripheral nerve neurolysis was selected as a Top Abstract at the CRT 2026 Meeting. Dr. Nikola Cesarovic will present the clinical feasibility and outcomes of this technique, which aims to improve precision in nerve-targeted therapies. The selection underscores the growing interest in innovative approaches to nerve modulation.
Read more →AMIX▲ +8%on this news
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
Autonomix Medical has released a new CEO Corner segment featuring CEO Brad Hauser, who discusses the company's publication strategy aimed at enhancing clinical credibility. Over the past 12 to 18 months, Autonomix has focused on submitting clinical data to peer-reviewed forums to validate its nerve-targeted technology. The company is developing a platform for treating various conditions, starting with pancreatic cancer pain.
Read more →AMIXAutonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
Autonomix Medical, Inc. (NASDAQ: AMIX) has been selected to present new long-term data on pain mitigation in patients with pancreatic cancer at the SSO 2026 Annual Meeting. The presentation will focus on their innovative transvascular RF energy-based approach to chronic pain management. Dr. Clarke Wilkirson will lead the discussion, emphasizing how this method may improve patient quality of life. Despite the promising potential, it is important to note that the technology remains investigational and not yet approved for marketing in the U.S.
Read more →AMIX▼ -5.2%on this news
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
Autonomix Medical will present final clinical data on its transvascular RF ablation technique for pain relief in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting. The presentation aims to showcase the potential of this innovative approach to address significant pain management challenges in pancreatic cancer patients. The event will take place from February 4-8, 2026, in Savannah, GA.
Read more →AMIXAutonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
Autonomix Medical presented new clinical data at the 2026 ASCO GI Cancers Symposium, highlighting effective pain relief in pancreatic cancer patients across all disease stages. The post hoc analysis from their PoC study showed consistent pain reduction, even in late-stage patients. This reinforces the potential of their nerve-targeted treatment approach.
Read more →AMIX▲ +8.3%on this news
Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
Autonomix Medical, Inc. has been granted a European patent for its innovative platform technology aimed at precision nerve-targeted therapies in cardiology. The patent enhances the company's intellectual property portfolio and supports its strategic position in a lucrative market. This technology could significantly improve treatment options for various cardiovascular conditions, including hypertension and heart failure.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
Autonomix Medical, Inc. recently participated in a Virtual Investor CEO Connect segment, where CEO Brad Hauser discussed the company's focus on expanding its intellectual property and exploring treatment opportunities beyond pancreatic cancer. The company aims to revolutionize nerve-targeted treatments with its advanced technology, which includes a catheter-based microchip sensing array. This innovative platform may address various conditions, including cardiovascular and chronic pain management.
Read more →AMIXAutonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Autonomix Medical, Inc. has announced that its abstract has been accepted for a poster presentation at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The presentation will focus on a long-term analysis of pain mitigation in pancreatic adenocarcinoma through transvascular RF energy-based ablation. The symposium is set to take place in San Francisco from January 8-10, 2026, highlighting the company's innovative approach to treating cancer-related pain.
Read more →AMIX▲ +10.2%on this news
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
Autonomix Medical, Inc. has released a new CEO Corner segment featuring President and CEO Brad Hauser. The discussion focuses on the company's strategic growth, emphasizing the importance of intellectual property and the exploration of new treatment opportunities beyond pancreatic cancer. The company aims to advance its innovative technologies for nerve-targeted treatments.
Read more →AMIX▼ -17.4%on this news
Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules
Autonomix Medical, Inc. has announced a successful private placement, raising approximately $5.0 million through the sale of shares and Series C warrants. The offering price is set at $1.1107 per share, with an exercise price for the warrants at $0.8607. The funds will contribute towards the development of their innovative medical technologies focused on nerve-targeted treatments, particularly for conditions like pancreatic cancer. However, the completion of the offering depends on standard closing conditions, and the company's technologies are still investigational.
Read more →AMIX▲ +58.2%on this newsshared move
Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
Autonomix Medical, Inc. announced positive results from a post-hoc subgroup analysis of its first-in-human study evaluating a novel transvascular energy ablation therapy for severe pancreatic cancer pain. The analysis showed significant improvements in patient-reported quality of life and symptom relief across various disease stages, particularly among late-stage patients. These findings align with previously reported pain reduction results and will guide the design of upcoming U.S. clinical trials set to begin in 2026. The therapy aims to enhance patient outcomes by targeting problematic nerves associated with cancer pain.
Read more →AMIXAutonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
Autonomix Medical, Inc. will present two studies at the TCT 2025 conference, showcasing their innovative approach to nerve-targeted treatments for pancreatic cancer pain. The presentations will discuss the safety and effectiveness of their transvascular energy delivery system. This marks a significant step in their clinical research efforts.
Read more →AMIXAutonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
Autonomix Medical, Inc. will showcase its innovative nerve-sensing and ablation platform at the 2025 Maxim Growth Summit in New York. The event, scheduled for October 22-23, will feature management participating in one-on-one meetings with investors. The company's technology aims to enhance diagnosis and treatment of nervous system diseases, particularly for pain management in pancreatic cancer.
Read more →AMIXAutonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
Autonomix Medical, Inc. has been granted U.S. Patent No. 12,369,852 for its innovative platform technology aimed at precision nerve-targeted therapies in cardiology. This patent strengthens the company's position in a lucrative market and could transform treatment options for various cardiac conditions. The technology focuses on precise treatment and mapping of cardiac tissues, potentially reducing reliance on traditional therapies.
Read more →AMIXAutonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
Autonomix Medical, Inc. has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses a post hoc analysis from the company's first-in-human proof-of-concept study and outlines progress towards initiating U.S. clinical trials, expected to start in 2026. The company is focused on developing innovative technologies for nerve-targeted treatments.
Read more →AMIXAutonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain. This study is a significant step towards achieving regulatory approvals, with plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2026. The company's innovative technology has the potential to address various medical conditions beyond pancreatic cancer.
Read more →AMIXAutonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress
Autonomix Medical, Inc. announced that its findings from the first phase of a first-in-human proof-of-concept clinical trial will be presented at the 2025 CIRSE Annual Congress in Barcelona. The presentation will focus on pain mitigation in pancreatic adenocarcinoma through neurolysis via transvascular radiofrequency ablation. This event emphasizes the role of AI in interventional radiology and aims to enhance treatment methodologies.
Read more →AMIX▼ -8.9%on this newsshared move
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
Autonomix Medical, Inc. has released results from a post hoc analysis of its proof-of-concept clinical trial, showing significant pain reduction and quality of life improvements. The trial achieved a remarkable 100% opioid-free outcome. Dr. Robert Schwartz discussed these findings in a recent virtual investor segment, highlighting the company's innovative approach to treating nervous system-related diseases.
Read more →AMIXAutonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
Autonomix Medical, Inc. has reported positive long-term results from a post hoc analysis of its PoC 1 study, demonstrating significant pain reduction and improved quality of life for patients suffering from severe pancreatic cancer pain. Notably, 100% of responders were opioid-free three months after the procedure. The company plans to expand its research into additional visceral cancer pain indications.
Read more →AMIX▲ +10.7%on this newsshared move
Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference
Autonomix Medical, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Brad Hauser will lead the presentation, and the company will also hold one-on-one meetings with investors. The event will be accessible via a webcast starting September 8, 2025, at 7:00 AM ET.
Read more →AMIXAutonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology
Autonomix Medical, Inc. has been granted a new European patent for its innovative catheter-based technology, enhancing its competitive edge in the medical device market. The patent covers a system for real-time physiological signal processing, applicable in various medical fields. This development positions Autonomix to capitalize on multi-billion-dollar market opportunities while advancing towards potential commercialization.
Read more →AMIXAutonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its CEO, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025. The webinar aims to engage investors with discussions followed by a Q&A session. Autonomix is focused on advancing treatments for nerve-related diseases and is developing a first-in-class technology that may improve diagnostics and treatment approaches, particularly for conditions like pancreatic cancer. Their investigational technology has not yet received marketing clearance in the U.S.
Read more →AMIXAutonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Autonomix Medical, Inc. is scheduled to present at the Webull Financial Corporate Connect Webinar Series from August 19-21, 2025. CEO Brad Hauser will lead the presentation on August 21 at 2:20 PM ET, sharing insights about the company's pioneering medical device technology. Autonomix focuses on precision nerve-targeted treatments, particularly for conditions like pancreatic cancer, and is developing groundbreaking catheter-based solutions to diagnose and treat peripheral nervous system diseases. The technology is still investigational and not yet approved for marketing in the U.S.
Read more →AMIXAutonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies
Autonomix Medical, Inc. has successfully completed the design review of its innovative intravascular nerve sensing catheter, a significant milestone that leads toward U.S. clinical trials. This catheter aims to provide real-time nerve mapping and targeted treatment, representing a potential breakthrough in neuromodulation and pain management. The company is preparing to submit an Investigational Device Exemption to initiate these trials and hopes to address multiple indications beyond its initial focus on pancreatic cancer pain. Autonomix's proprietary technology could redefine treatment strategies in various therapeutic areas.
Read more →AMIX▼ -24%on this news
Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Autonomix Medical, Inc. (AMIX) participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference. CEO Brad Hauser highlighted his commitment to the company's innovative technology aimed at revolutionizing the diagnosis and treatment of nervous system diseases. The company's platform technology features a catheter-based microchip sensing array that could significantly improve the detection of neural signals. Autonomix is focusing on developing this technology for conditions such as pancreatic cancer, which currently has no reliable treatment options.
Read more →AMIX▼ -24%on this news
Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds
Autonomix Medical, Inc. has announced the immediate exercise of existing warrants, expecting to raise approximately $2.5 million in gross proceeds. The company will issue new warrants that are exercisable for an aggregate of up to 1,477,596 shares of common stock at a reduced exercise price. The funds raised will be used for working capital and general corporate purposes, and the transaction is set to close on July 23, 2025, pending customary closing conditions. Autonomix is focused on developing innovative technologies for the treatment of nervous system diseases, currently targeting pancreatic cancer pain management.
Read more →AMIX▲ +15.8%on this newsshared move
Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications
Autonomix Medical, Inc. has been granted a new U.S. patent for its smart torquer device, aimed at enhancing the manipulation of intravascular devices during minimally invasive procedures. This innovation is intended for use in precision nerve-targeted treatments across various high-need medical fields, including cardiology and chronic pain management. The newly issued patent marks an important addition to Autonomix's growing intellectual property portfolio, which includes over 80 issued patents. However, the technology is still investigational and not yet cleared for commercial use in the United States.
Read more →AMIX▼ -21.9%on this news
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
Autonomix Medical, Inc. has commenced treatment of the first patient in its PoC 2 phase, expanding its clinical study to address additional visceral cancers. This move, stemming from promising results in PoC 1, aims to mitigate cancer pain and potentially doubles the addressable market from its original focus on pancreatic cancer pain. The technology holds promise across a spectrum of diseases, but the company acknowledges risks associated with its forward-looking statements and clinical results.
Read more →AMIX▲ +60.8%on this newsshared move
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
Autonomix Medical, Inc. has been granted a new U.S. patent that enhances its catheter-based platform technology aimed at treating nerve-related conditions. This innovation is expected to improve patient outcomes and strengthen the company's competitive position in the multi-billion-dollar market of nerve-focused therapeutics. Plans for U.S. clinical trials are set for 2025, specifically targeting pain management associated with pancreatic cancer. However, the company acknowledges that its technology remains investigational and will require successful trial outcomes for commercialization.
Read more →AMIX▼ -15.9%on this news
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Autonomix Medical, Inc. has received Ethics Committee authorization to expand its proof-of-concept clinical study, allowing the company to double its target market by including additional visceral cancers. The initial study in pancreatic cancer pain showed promising results, with significant pain reduction and less reliance on opioids. The follow-on PoC 2 phase is set to begin patient enrollment in June 2025. This expansion aligns with Autonomix's strategy of exploring multiple indications for its innovative ablation technology.
Read more →AMIX▲ +9.2%on this news
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Autonomix Medical, Inc. has been granted a key U.S. patent for its innovative catheter-based technology aimed at nerve-mapping and denervation. The patent, No. 12,257,071, covers advanced systems combining nerve mapping and radiofrequency ablation techniques to treat various nerve-related conditions. With over 80 issued patents and continued expansion into global markets, Autonomix aims to revolutionize pain management and other neurological treatments. The company is set to submit an Investigational Device Exemption in 2025 to begin U.S. clinical trials for treating pancreatic cancer pain.
Read more →AMIX▼ -5.9%on this newsshared move
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Closing Bell Series on May 22, 2025, where CEO Brad Hauser will present a corporate overview. The company focuses on developing a catheter-based microchip sensing array aimed at improving the detection and differentiation of neural signals. This technology has potential applications in treating various medical conditions, beginning with pancreatic cancer. The event will include a live Q&A session, allowing investors to submit questions directly to the company.
Read more →AMIXAutonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
Autonomix Medical has released a patient testimonial demonstrating significant pain relief following its first-in-human proof-of-concept trial for treating pancreatic cancer pain. The trial showed a mean pain reduction of 53.3% at 7 days and 59.2% at 4-6 weeks post-procedure, with 100% of responders opioid-free at one week. The trial results highlight the potential of Autonomix's technology to improve quality of life for late-stage cancer patients while managing pain effectively. The company plans to expand its protocol to include additional indications for visceral cancers and earlier stages of pancreatic cancer.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Autonomix Medical, Inc. (NASDAQ: AMIX) announced insights from its first-in-human trial phase, showcasing effective pain reduction methods for pancreatic cancer patients. Chief Medical Officer Dr. Robert Schwartz participated in a virtual segment, outlining plans for a subsequent study targeting visceral cancers, with initiation expected in Q2 2025. The company's innovative technology aims to enhance diagnosis and treatment for diseases involving the nervous system.
Read more →AMIX▼ -7.5%on this news· ran to -21% by day 3shared move
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
Autonomix Medical, Inc. has announced promising results from the initial phase of its first-in-human proof-of-concept trial for pancreatic cancer pain management. All 20 enrolled patients achieved clinically meaningful pain reduction, with 100% of responders being opioid-free at seven days post-procedure. The trial results support the company's plans to initiate a follow-up market expansion study targeting additional visceral cancers and earlier stage pancreatic cancer. These advancements could potentially double the market opportunity for the company's innovative technology.
Read more →AMIXAutonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
Autonomix Medical, Inc. announced that its technology and early proof-of-concept study results will be featured in a poster presentation at EuroPCR 2025 in Paris. The presentation focuses on a catheter-based approach aimed at alleviating severe pain from pancreatic cancer. Autonomix aims to revolutionize treatments for conditions involving the peripheral nervous system with its investigational technology. This notable participation in a leading medical conference underscores the potential impact of their innovations in interventional cardiovascular medicine.
Read more →AMIXAutonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Autonomix Medical, Inc. announced the approval of an inducement stock option for a new non-executive employee, in line with Nasdaq Listing Rule 5635(c)(4). The grant includes options to purchase 5,000 shares of common stock, with a ten-year term and a vesting schedule contingent on the employee's continued service. Autonomix focuses on innovative technologies for diagnosing and treating nervous system diseases, with its first application targeting pancreatic cancer. The technology is still in investigational stages and has not yet received marketing clearance in the U.S.
Read more →AMIX▲ +6%on this newsshared move
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
Autonomix Medical, Inc. has announced the granting of a new European patent for its proprietary catheter-based technology, which can regulate organ and tumor growth. This patent highlights the company's commitment to expanding its innovative medical devices aimed at treating diseases that affect the nervous system. With over 80 issued patents and 40 pending applications, Autonomix is positioned for significant growth in its clinical endeavors. The technology could have extensive applications, particularly in addressing conditions related to prostate tumors and other lower urinary tract diseases, and the company anticipates submitting an Investigational Device Exemption (IDE) for U.S. clinical trials in 2025.
Read more →AMIXAutonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
Autonomix Medical, Inc. has engaged a team of leading medical experts to guide its U.S. clinical and regulatory path for a De Novo application to the FDA. The company is preparing to commence clinical studies in 2025, focusing on their innovative technology aimed at treating pain associated with pancreatic cancer. This technology includes a catheter-based microchip sensing array designed to enhance the detection of neural signals. With strong encouragement from its CEO, the company is optimistic about its progress, awaiting further FDA approvals.
Read more →AMIXAutonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
Autonomix Medical, Inc. announced that an abstract showcasing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO) in Rotterdam. The presentation will highlight the company's catheter-based transvascular RF neural ablation technology aimed at treating severe pain associated with pancreatic cancer. The ECIO is recognized for gathering top experts in interventional oncology to share knowledge and advancements in the field. Autonomix's innovative technology promises to enhance diagnosis and treatment options for diseases related to the nervous system.
Read more →AMIX▲ +10.6%on this newsshared move
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
Autonomix Medical, Inc. announced the issuance of a new U.S. patent for its proprietary catheter-based technology that captures and processes physiological signals. This advancement can improve treatment for various conditions, including pancreatic cancer pain. The company plans to initiate U.S. clinical trials in 2025 to support commercialization efforts. CEO Brad Hauser emphasized the potential of this technology to revolutionize treatments linked to nerve activity across multiple medical fields.
Read more →AMIX▼ -9.8%on this news
Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation
Autonomix Medical, Inc. has achieved a significant milestone with the completion of the integration of its Apex 6 Radiofrequency Generator into the Autonomix Sensing and RF Ablation System. This advancement positions the company to submit an Investigational Device Exemption application to the U.S. FDA, targeting the initiation of clinical trials for pancreatic cancer pain in 2025. The company aims to provide effective pain relief through innovative nerve-targeted treatments, demonstrating early promising clinical results for this pressing medical need.
Read more →AMIXAutonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Autonomix Medical, Inc. announced that its abstract was accepted for a poster presentation at the 2025 Society of Interventional Radiology Annual Scientific Meeting. The study focuses on an innovative technique for pain mitigation in pancreatic adenocarcinoma through neurolysis and transvascular RF energy-based ablation. The company's technology aims to revolutionize the diagnosis and treatment of diseases affecting the nervous system, although it remains investigational and has not yet received marketing clearance. The meeting will take place from March 29 to April 2, 2025, in Nashville, Tennessee.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit
Autonomix Medical, Inc. (NASDAQ: AMIX) has announced that its CEO, Brad Hauser, will present at the LSI USA ’25 Emerging Medtech Summit on March 18, 2025. The company is focused on innovative technologies for diagnosing and treating nervous system diseases, with a particular emphasis on an advanced catheter-based microchip sensing array. This platform technology, which has not yet received marketing clearance, is being developed to treat conditions like pancreatic cancer, aiming for improved sensitivity in neural signal detection. Autonomix will also engage in one-on-one meetings with qualified investors during the summit.
Read more →AMIXAutonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting
Autonomix Medical, Inc. (NASDAQ: AMIX) is set to present its catheter-based technology at the 2025 CRT Annual Meeting. The presentation will focus on findings from the Elpis study concerning severe pancreatic cancer pain. The event, held in Washington, DC from March 8-11, 2025, will provide an educational forum to discuss innovative cardiovascular technologies, where Autonomix seeks to highlight its advancements in precision nerve-targeted treatments.
Read more →AMIXAutonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Autonomix Medical, Inc. (NASDAQ: AMIX) participated in the Virtual Investor "Top 5 for '25" On-Demand Conference, where CEO Brad Hauser discussed the company's innovative technologies and potential for 2025. The company focuses on advancing precision nerve-targeted treatments and features a platform technology that significantly enhances the detection of neural signals. Initial applications include addressing pain related to pancreatic cancer, a condition currently lacking reliable solutions. The company's technology is investigational and not yet cleared for marketing in the U.S.
Read more →AMIXAutonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Autonomix Medical, Inc. (NASDAQ: AMIX) released its third quarter fiscal results for 2025, highlighting progress in its clinical trial focused on pancreatic cancer pain management. The company achieved key milestones, including design lock for its RF ablation catheter and planning for U.S. clinical trials set to begin in 2025. Financially, while losses have decreased year-over-year, higher operational costs were noted. Autonomix continues to pursue FDA approval with an expanded patent portfolio backing its innovative technology.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Autonomix Medical, Inc. has announced the publication of its next CEO Corner segment, featuring insights from CEO Brad Hauser on the recent J.P. Morgan Healthcare Conference. The company focuses on developing innovative medical technologies aimed at diagnosing and treating diseases of the nervous system. Their pioneering platform utilizes a catheter-based microchip sensing array, which boasts significantly enhanced sensitivity for neural signal detection. Initially, their technology is being developed to treat pain associated with pancreatic cancer, offering potential for wider applications across various medical conditions.
Read more →AMIX▲ +9.8%on this news
Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025
Autonomix Medical, Inc. announced the finalization of the design for its ASIC microchip intended for human use, marking a significant milestone in its development. The company has successfully completed in vivo preclinical and extensive bench testing prior to this design lock. Autonomix is moving forward with plans to submit an Investigational Device Exemption, aiming to initiate a pivotal clinical trial in the United States by 2025. The technology is primarily focused on treating pain from pancreatic cancer, aiming to improve the quality of life for patients in need.
Read more →AMIX▲ +10.5%on this newsshared move
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Closing Bell Series on January 22, 2025, at 4:00 PM ET. CEO Brad Hauser will present a corporate overview, discuss business outlook, and answer live questions from the audience. The company focuses on advanced technologies for diagnosing and treating diseases that affect the nervous system, claiming their platform has a significantly higher sensitivity for neural signal detection than existing methods. Their initial application targets pain management in pancreatic cancer, although the technology is still investigational.
Read more →AMIX▼ -8.7%on this newsshared move
Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting
Autonomix Medical, Inc. announces that its abstract titled 'Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five Lead-In Patients' has been accepted for poster presentation at the 2025 Society of Interventional Oncology Annual Scientific Meeting. The meeting will occur from January 30 to February 3, 2025, in Las Vegas, NV. The company's innovative technology aims to enhance pain treatment and diagnosis for conditions affecting the nervous system, particularly pancreatic cancer.
Read more →AMIX▲ +20.6%on this news
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology
Autonomix Medical, Inc. has announced the granting of U.S. patent 12,064,256, which covers systems and methods for treating cancerous tumors and related pain. The company's innovative catheter-based technology demonstrated significant reductions in metastases and tumor mass in preclinical studies, specifically targeting pancreatic cancer pain. With a growing patent portfolio and ongoing clinical trials, Autonomix aims to further explore the clinical applications of its technology. However, the company acknowledges the inherent risks associated with forward-looking statements regarding its potential impact.
Read more →AMIX▼ -5.1%on this newsshared move
Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality
Autonomix Medical, Inc. has appointed Julie Manchester as Vice President of Regulatory Affairs and Quality, aiming to strengthen its clinical and regulatory efforts. The company is on schedule to submit an Investigational Device Exemption (IDE) and initiate a pivotal clinical trial in 2025 for its innovative catheter-based sensing technology. Significant progress has been made with successful animal testing and design lock completion. The leadership change is positioned as a strategic move to meet regulatory requirements and advance their technology targeting diseases of the nervous system.
Read more →AMIX▼ -6.7%on this news
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
Autonomix Medical, Inc. announced that it has achieved a design lock for its RF ablation catheter following the successful completion of animal tests. This milestone is crucial as the company prepares to submit an Investigational Device Exemption (IDE) and plans to begin a pivotal clinical trial in the second half of 2025 to pursue FDA approval. The technology aims to address chronic pain, particularly for pancreatic cancer patients, and could transform treatment paradigms in pain management. Autonomix continues to build its team to support its clinical and regulatory initiatives ahead of the expected trial.
Read more →AMIXAutonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
Autonomix Medical, Inc. announced the successful closing of a $10 million underwritten public offering, which included a partial exercise of an over-allotment option. The offering consisted of common stock and pre-funded warrant units priced at $6.54 and $6.539 respectively. The company plans to utilize the proceeds for clinical trials, research and development, and to enhance its intellectual property portfolio. This financing is aimed at advancing their novel technologies for nerve-targeted treatments in conditions such as pancreatic cancer.
Read more →AMIX▼ -53.6%on this newsshared move
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
Autonomix Medical, Inc. has announced the pricing of an underwritten public offering, expected to generate approximately $9.0 million in gross proceeds. The offering encompasses 1,376,287 common stock units at a price of $6.54 per unit, accompanied by Series A warrants. The net proceeds are intended to fund clinical trials, research and development, and to support working capital efforts. The closing of the offering is anticipated on or about November 25, 2024, subject to customary conditions.
Read more →AMIXAutonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Autonomix Medical, Inc. has reported its financial results for Q2 of fiscal year 2025, highlighting advancements in its ongoing proof-of-concept clinical trial targeting pain from pancreatic cancer. Notably, preliminary results show a 100% reduction in opioid use among early responders and an 83% reduction in overall pain levels post-procedure. The company has reached 60% enrollment in the trial and anticipates key milestones, including trial completion and potential FDA clearance by 2027. Despite significant advancements, the company also reported a $2.8 million net loss for the quarter, primarily due to increased expenses related to its clinical trial and administrative costs.
Read more →AMIXAutonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
Autonomix Medical, Inc. has reported encouraging preliminary results from its ongoing clinical trial aimed at treating pancreatic cancer pain with transvascular energy delivery. The trial, which has successfully enrolled 15 patients and achieved a 79% responder rate, shows a 63% reduction in pain levels at 7 days post-procedure, with no need for opioids among respondents. There were no significant adverse events, reinforcing the potential of their innovative technology for improving quality of life in patients suffering from this debilitating condition. The company's CEO expressed optimism about changing the treatment paradigm for pancreatic cancer pain as they proceed with full enrollment.
Read more →AMIXAutonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical, Inc. recently shared positive results from a 4-6 week follow-up data involving the first five patients in their human clinical trial. The trial evaluates the safety and effectiveness of a novel transvascular energy delivery system aimed at alleviating pain in pancreatic cancer patients. Dr. Robert Schwartz, the Chief Medical Officer, participated in a Virtual Investor segment discussing the significance of these results. The technology may offer a groundbreaking approach to diagnosing and treating nervous system-related conditions.
Read more →AMIXAutonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
Autonomix Medical, Inc. (NASDAQ: AMIX) will hold a Virtual Investor segment on October 30, 2024, where Chief Medical Officer Dr. Robert Schwartz will discuss findings from a clinical trial's follow-up data. This clinical trial involves a first-in-class catheter-based microchip sensing array designed to enhance the diagnosis and treatment of nervous system diseases. The innovative technology aims to provide unprecedented precision in the detection of neural signals, particularly in conditions like pancreatic cancer, which causes severe pain. While this technology remains investigational and has not yet received marketing clearance in the U.S., it represents a significant advancement in medical device capabilities.
Read more →AMIXAutonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
Autonomix Medical, Inc. has announced its participation in the 2024 Healthcare Virtual Summit hosted by Maxim Group LLC, with CEO Brad Hauser scheduled for a fireside chat. The company specializes in innovative technologies aimed at improving the diagnosis and treatment of diseases affecting the nervous system. Their leading-edge platform technology, featuring a catheter-based microchip sensing array, is designed to detect neural signals with enhanced sensitivity. While currently investigational, the technology holds promise for addressing various medical indications including chronic pain and pancreatic cancer.
Read more →AMIXAutonomix Selected to Present at the 2024 Octane Medical Innovation Forum
Autonomix Medical, Inc. has been selected to present at the 2024 Octane Medical Innovation Forum on October 8-9, 2024. CEO Brad Hauser will discuss the company's advanced technology for nerve-targeted treatments, including a highly sensitive catheter-based sensing platform. This technology aims to enhance the diagnosis and treatment of conditions affecting the nervous system, particularly chronic pain, hypertension, and cardiology. The presentation marks a significant opportunity for the company within the medical device sector.
Read more →AMIXAutonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
Autonomix Medical, Inc. has reported significant preliminary results from its ongoing clinical trial evaluating a novel treatment for pancreatic cancer pain. In the first five lead-in patients, 60% exhibited an 83% reduction in pain levels from an average score of 8 to 1.33 at the 4-6 week post-procedure mark. All responders reported clinically meaningful pain relief, while the trial is on track for full enrollment by the end of 2024. However, results varied, with patients treated via brachial access experiencing no improvement.
Read more →AMIXAutonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
Autonomix Medical, Inc. (NASDAQ: AMIX) will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Brad Hauser will lead the presentation, and management is open to one-on-one meetings with investors attending the conference. Autonomix's innovative medical technology aims to revolutionize the diagnosis and treatment of nervous system diseases, particularly targeting indications like chronic pain and pancreatic cancer. The company’s novel catheter-based microchip sensing array promises enhanced sensitivity in detecting neural signals. The technology is still investigational and not yet approved for marketing in the U.S.
Read more →AMIXAutonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Autonomix Medical, Inc. announced that its abstract has been accepted for a podium presentation at the 2024 CIRSE Annual Congress in Lisbon. The presentation will showcase interim findings from a proof-of-concept clinical trial focused on AI applications in interventional radiology, particularly for managing pain in pancreatic cancer. CEO Brad Hauser emphasized the importance of engaging with the scientific community and aligning data release with the publication strategy. The event will take place on September 16, 2024, featuring Dr. Askar Sabirov as the presenter.
Read more →AMIXAutonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
Autonomix Medical, Inc. announced its financial results for Q1 FY2025, reporting positive developments in its ongoing proof-of-concept clinical trial for pain associated with pancreatic cancer. The trial's initial results showed significant pain reduction in patients, with further data expected by the end of Q3 2024. The company, now under new leadership, aims to advance its catheter-based technology for nerve-targeted treatments and has outlined several key upcoming milestones in its development plan. However, it also reported increased losses and rising R&D costs during this period.
Read more →AMIXAutonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
Autonomix Medical, Inc. has finalized a licensing deal with RF Innovations to acquire rights to the FDA-cleared Apex 6 Radiofrequency Generator, which will be vital for their ablation system. This agreement strengthens Autonomix’s supply chain and accelerates its development pathway toward FDA clearance. The technology is aimed primarily at alleviating pain from pancreatic cancer and may address multiple indications in the future. Autonomix plans to swiftly integrate RF Innovations' manufacturing partner to enhance product development.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement
Autonomix Medical, Inc. has announced its participation in a Virtual Investor segment where CEO Brad Hauser discussed a new licensing agreement with RF Innovations, Inc. This agreement allows Autonomix to use FDA-cleared ablation technology for the development of its innovative neurodiagnostic and treatment devices. The company's new technology platform promises significant advancements in diagnosing and treating diseases of the peripheral nervous system. Initially, they will focus on conditions like pancreatic cancer, which lacks reliable treatment options.
Read more →AMIXAutonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
Autonomix Medical, Inc. has entered a definitive agreement to license the Apex 6 Radiofrequency Generator from RF Innovations, enhancing its ablation system for pain management. This agreement, which grants a perpetual license, reinforces Autonomix's FDA regulatory pathway as the generator is already cleared for use. The company intends to leverage this technology to improve its treatment options for conditions such as pancreatic cancer-related pain. The transaction is expected to close by the end of July 2024.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
Autonomix Medical, Inc. has announced the launch of its CEO Corner platform, which aims to provide stakeholders with in-depth updates regarding press releases, corporate events, and development progress. CEO Brad Hauser emphasized the importance of transparency and effective communication to enhance stakeholder engagement. The company is focused on advancing pioneering technologies to transform the diagnosis and treatment of nervous system-related diseases. However, their investigational technology has not yet received marketing approval, and certain risks are associated with meeting clinical timelines.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
Autonomix Medical, Inc. has reported preliminary positive results from a clinical trial focused on treating pancreatic cancer pain. Chief Medical Officer Dr. Robert Schwartz shared insights in a Virtual Investor segment, highlighting advancements in pain management through their innovative technology. The ongoing proof-of-concept trial aims to test the safety and effectiveness of a new method to address pain related to pancreatic cancer. Despite promising initial feedback, the technology remains investigational and is not yet available commercially.
Read more →AMIXAutonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical has announced preliminary positive results from the first five patients in its ongoing clinical trial aimed at alleviating pancreatic cancer-related pain. Following a transvascular radiofrequency ablation procedure, 60% of subjects reported substantial pain reduction, with an average decrease in pain scores from 8.0 to 1.67. Patients also experienced significant improvements in overall health and quality of life. The trial is on track for complete enrollment by the end of 2024, despite the initial patient results not being included in the final analysis.
Read more →AMIXAutonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
Autonomix Medical, Inc. has appointed Brad Hauser as the new President and Chief Executive Officer, following Lori Bisson's shift to Executive Vice Chairman. Hauser brings over 20 years of experience in medical technology and a strong track record of driving innovations and growth in the field. The leadership transition is crafted to support the company’s next phase of development, particularly in advancing technologies targeting diseases of the nervous system. The company aims to enhance its clinical programs and pursue global regulatory approvals.
Read more →AMIXAutonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
Autonomix Medical, Inc. will announce preliminary topline results from the first five lead-in patients in its ongoing clinical trial on June 18, 2024. This trial evaluates the safety and effectiveness of a new technology for treating pain associated with pancreatic cancer. The company plans to engage with investors and analysts through a live webcast to discuss the results. The technology aims to provide a revolutionary approach to diagnosing and treating diseases affecting the nervous system.
Read more →AMIXAutonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical, Inc. has received Ethics Committee approval for a protocol amendment in its human clinical trial aimed at treating pain associated with pancreatic cancer. This trial focuses on evaluating the effectiveness of a catheter-based technology that utilizes transvascular energy for nerve ablation. The company plans to report topline results from initial 'lead-in' patients soon. The amendment includes gathering additional data to refine the safety and efficacy of the procedure. Autonomix anticipates completing patient enrollment by the end of this year.
Read more →AMIXAutonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
Autonomix Medical, Inc. reported its fiscal year 2024 financial outcomes, highlighting significant operational progress in advancing its technology for treating nervous system diseases. The company completed an IPO, raising $11.2 million, and initiated a clinical study on using RF ablation for pancreatic cancer pain. Despite incurring net losses of $15.4 million, Autonomix boasts a cash runway that will support operations through the first quarter of 2025. The upcoming release of topline data from the first five patients in their study is anticipated in June 2024, augmenting the company's potential impact in the oncology space.
Read more →AMIXAutonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
Autonomix Medical, Inc. announced promising results from a preclinical study investigating the use of nerve ablation in slowing tumor metastasis in pancreatic cancer. The study showed a statistically significant reduction in both tumor mass and metastases in treated mice compared to controls. CEO Lori Bisson highlighted the potential clinical implications of these findings while emphasizing the technology's aim to improve treatment for patients suffering from pancreatic cancer and associated pain. Further studies are planned to explore the transition of these results into clinical practice.
Read more →AMIXAutonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip
Autonomix Medical, Inc. has partnered with NoiseFigure Research, Inc. to enhance its proprietary ASIC microchip technology for neurology applications. This collaboration aims to prepare for a pivotal trial planned for 2025, focusing on improving pain management for pancreatic cancer. The upgraded microchip promises superior sensitivity in detecting neural signals, potentially revolutionizing treatment approaches for various diseases. However, as with any development, the company acknowledges risks associated with the timely execution of its plans.
Read more →AMIXAutonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that CEO Lori Bisson will present at the LIVE! with Webull Corporate Connect Virtual Biotech Investment Webinar on May 1, 2024. The company is focused on pioneering technologies for diagnosing and treating nervous system diseases. Their leading technology is a catheter-based microchip sensing array that offers unprecedented sensitivity in detecting neural signals, with initial applications targeting pancreatic cancer pain. Autonomix's approach has the potential to expand into various medical indications.
Read more →AMIXAutonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
Autonomix Medical, Inc. has announced the issuance of U.S. patent 10,143,419 for its innovative catheter-based technology aimed at treating cancer-related pain, with an initial focus on pancreatic cancer. This patent adds to a comprehensive portfolio of over 100 patents, underscoring the company's commitment to advancing novel pain management solutions. The technology is designed to accurately detect and target problematic neural signals, offering the potential to revolutionize how pain is managed compared to current opioid-based methods. Autonomix aims to address significant market opportunities within the $100 billion pain management sector.
Read more →AMIXAutonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation
Autonomix Medical, Inc. has announced positive findings from a preclinical study of its catheter-based sensing technology, showing its potential to improve renal denervation. The study demonstrated successful targeting and sensing of nerves surrounding the renal artery, which are critical for blood pressure regulation. This innovation could enhance the accuracy of current renal denervation procedures by eliminating blind ablation techniques. However, further clinical studies are necessary to confirm efficacy and safety in human patients, especially in treating conditions such as hypertension.
Read more →AMIXAutonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Lunch Break on April 11, 2024. The event will feature members of the management team discussing their roles and addressing live questions from participants. The company aims to revolutionize disease diagnosis and treatment for the nervous system, with a technology platform that shows significant potential in various medical indications, starting with pancreatic cancer pain.
Read more →AMIXAutonomix to Present at the MedInvest Biotech & Pharma Investor Conference
Autonomix Medical, Inc. (AMIX) has announced that its CEO, Lori Bisson, will present at the MedInvest Biotech & Pharma Investor Conference on April 4, 2024. The conference will provide an opportunity for management to engage in one-on-one meetings with investors. Autonomix focuses on innovative medical technologies for diagnosing and treating diseases of the nervous system, including its first-in-class technology for pancreatic cancer pain.
Read more →AMIXAutonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024
Autonomix Medical, Inc. (NASDAQ: AMIX) will present at the Benzinga Virtual Healthcare Summit 2024 on March 20, 2024, at 11:50 AM ET. CEO Lori Bisson will discuss the company's advancements in innovative technologies for diagnosing and treating diseases involving the nervous system. The summit brings together prominent figures in healthcare to explore various topics including AI, telemedicine, and medical devices. Autonomix is developing a microchip sensing technology that enhances sensitivity in detecting neural signals, initially aimed at addressing pancreatic cancer pain.
Read more →AMIXAutonomix Appoints Jennifer Cook as Chief Business Officer
Autonomix Medical, Inc. has appointed Jennifer Cook as the Chief Business Officer, aiming to strengthen its business strategy and execution. Cook brings 28 years of experience, including success in building early-stage companies into integrated businesses. She previously held key marketing positions at MedShift and Soliton, the latter of which was acquired by AbbVie. Autonomix focuses on advancing medical technologies for diagnosing and treating nervous system diseases, with significant expectations for future growth in various indications.
Read more →AMIXAutonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
Autonomix Medical, Inc. has completed the first three patient procedures in a proof-of-concept clinical trial aimed at evaluating transvascular radiofrequency ablation for reducing pain in pancreatic cancer patients. The initial results showed no significant adverse events, indicating a milestone for both the trial and the company's technology. The trial will enroll 20 subjects and aims to address a significant unmet need for effective pain management in pancreatic cancer, which is currently limited by existing treatment options. Enrollment is expected to conclude by the end of 2024.
Read more →AMIXAutonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
Autonomix Medical, Inc. has initiated patient enrollment for its first human clinical trial, targeting pain management in pancreatic cancer using a novel transvascular radiofrequency ablation technique. This innovative approach seeks to address chronic pain in patients who often experience insufficient relief from standard opioid treatments. The trial aims to successfully ablate somatic nerves and mitigate pain with an expected enrollment of 20 participants and completion anticipated by the end of 2024. The company plans to continue advancing its technology with several milestones outlined leading up to anticipated FDA submission in 2027.
Read more →AMIXBreakthrough Technology That Could Transform Nerve - Targeted Treatments Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operation
AMIX is advancing a groundbreaking catheter-based technology aimed at transforming nerve-targeted treatments, particularly for pancreatic cancer-related pain. Currently in the clinical trial phase, this innovation boasts over 3,000 times greater sensitivity than existing methods. While the technology presents a significant market opportunity, the company acknowledges the uncertainties surrounding its forward-looking statements and the competitive environment. Investors are encouraged to consider these factors as they monitor AMIX's developments.
Read more →AMIXAutonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
Autonomix Medical, Inc. announced it has signed key agreements to initiate a proof-of-concept human clinical trial targeting pancreatic cancer pain through transvascular RF ablation. The company will collaborate with Clinical Accelerator and Qmed to manage various aspects of the trial. Enrollment is expected to begin shortly and aims to mitigate pain in patients with pancreatic cancer using a novel catheter-based technology. Autonomix anticipates completing patient enrollment by the end of 2024, with a series of milestones laid out for the development of their ablation technology.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in a Virtual Investor Lunch Break on February 29, 2024, featuring CEO Lori Bisson. The event aims to provide a corporate overview and discuss the company's innovative technologies for diagnosing and treating nervous system diseases. The company's leading technology platform offers significantly enhanced capabilities in detecting neural signals, with potential applications across various medical fields. Autonomix is initially focusing on solutions for pancreatic cancer pain while aiming to address multiple other indications.
Read more →AMIXAutonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
Autonomix Medical, Inc. has completed key milestones in preparing for its proof-of-concept clinical trial focused on treating pancreatic cancer pain with transvascular radiofrequency ablation. The company has secured Principal Investigators and successfully trained them, with plans to begin patient enrollment shortly. This innovative approach aims to address limitations of existing treatments, relying on a catheter-based technology that can precisely target nerves associated with pain. Enrollment for the study is expected to be finished by the end of 2024, contingent on the progress of upcoming milestones.
Read more →AMIXAutonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
Autonomix Medical, Inc. has announced the completion of site initiation for its proof-of-concept human clinical trial assessing the use of transvascular RF ablation in alleviating pancreatic cancer pain. The trial, which aims to enroll twenty patients, represents a significant advancement in addressing the issue of pain management that is often inadequately addressed by current treatments like opioids. The company’s novel technology is designed to provide a more precise targeting of nerves associated with pain, which could lead to more effective outcomes. Patient enrollment is expected to commence within the same quarter of the announcement, with the company pursuing additional regulatory milestones over the next few years.
Read more →AMIXAutonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
Autonomix Medical, Inc. reported its third quarter FY2024 financial results, highlighting its focus on developing innovative technology for treating diseases of the nervous system, specifically addressing pancreatic cancer pain. The company completed an $11.2 million IPO and plans to initiate a pioneering study on radiofrequency ablation for pain management in Q1 CY2024. Despite recent advancements and funding, Autonomix faces financial risks, having incurred a substantial net loss and limited cash resources projecting operations to Q1 CY2025. The company's pipeline suggests potential for growth in the medical technology market.
Read more →AMIXAutonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
Autonomix Medical, Inc. has received authorization from the Uzbekistan Ethics Committee to begin a proof-of-concept human clinical study using transvascular radiofrequency ablation technology for treating pancreatic cancer pain. This marks the first-ever evaluation of this method aimed at alleviating severe pain for patients suffering from this illness. The company plans to start patient enrollment in the first quarter of 2024 and expects to complete it before the end of the year. This innovative approach may offer a better alternative to existing pain management treatments, such as opioids, which often have limited effectiveness and adverse side effects.
Read more →AMIX▲ +10.8%on this newsshared move
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
Autonomix Medical, Inc. (NASDAQ: AMIX) will present at the Virtual Investor New to the Street Event on February 7, 2024, at 10:00 AM ET. Key management personnel, including CEO Lori Bisson and CMO Dr. Robert Schwartz, will provide a corporate overview and answer questions from investors. The company's technology aims to revolutionize the diagnosis and treatment of diseases involving the nervous system, specifically targeting pancreatic cancer pain and other indications. A live video webcast will be available, along with a replay for subsequent viewing.
Read more →AMIXAutonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
Autonomix Medical, Inc. will ring the Nasdaq Stock Market Closing Bell on February 1, 2024, celebrating their recent IPO and listing. CEO Lori Bisson will lead the ceremony, which recognizes the company's achievement and innovative technologies in diagnosing and treating nervous system diseases. Autonomix's first-in-class technology aims to address various medical conditions, starting with pancreatic cancer pain. The event will be streamed live, showcasing Autonomix's commitment to growth and advancement within the medical device industry.
Read more →AMIXAutonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
Autonomix Medical, Inc. has regained exclusive worldwide rights to its technology for use in cardiology, a move that broadens its development opportunities. This follows the termination of a previous licensing agreement with Impulse Medical. The company is also focusing on its pancreatic cancer pain development program and plans to commence its first-in-human clinical study this quarter. Autonomix's catheter-based technology aims to improve the diagnosis and treatment of diseases related to the nervous system.
Read more →AMIXAutonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
Autonomix Medical, Inc. has successfully regained exclusive worldwide rights to its innovative cardiology technology from Impulse Medical, enhancing its development potential. The company is positioned for growth following the completion of its IPO and as it advances with preclinical efforts. CEO Lori Bisson highlighted the importance of this re-acquisition for the company's development strategy and ongoing projects, particularly in pancreatic cancer pain treatment. Autonomix aims to revolutionize the treatment of diseases involving the nervous system through its advanced catheter-based sensing technology.
Read more →AMIXAutonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
Autonomix Medical, Inc. (AMIX) has begun trading on NASDAQ as of January 29, 2024, marking a significant milestone for the company. The medical device firm is developing innovative technology aimed at revolutionizing treatment for nervous system diseases, initially targeting pancreatic cancer. Their catheter-based sensing technology promises enhanced precision in nerve treatment, potentially offering a better alternative to traditional methods. However, the company acknowledges inherent risks associated with the development of their technology and market competition.
Read more →AMIXAutonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
Autonomix Medical, Inc. has successfully closed its initial public offering, raising $11.2 million from the sale of 2,234,222 shares at $5.00 each. The shares are set to begin trading on NASDAQ on January 29, 2024, under the ticker symbol 'AMIX.' The company focuses on innovative technologies for the diagnosis and treatment of diseases affecting the nervous system, with their advanced microchip sensing array projecting significant benefits in sensitivity. The firm plans to initially target conditions related to pancreatic cancer pain and pancreatitis pain.
Read more →AMIXAutonomix Medical, Inc. Successfully Completes Preclinical Safety Study to Support Program Advancement into First-in-Human Clinical Study to Treat Pancreatic Cancer Pain Through Transvascular Ablation
Autonomix Medical, Inc. has successfully completed a preclinical safety study of its innovative ablation technology designed to manage pain associated with pancreatic cancer. The study, conducted in a porcine multi-arterial model, demonstrated effective energy delivery and no reported complications. The company now plans to advance to its first-in-human clinical study, expected to begin enrollment in early 2024, leveraging this positive safety outcome.
Read more →AMIXAutonomix Medical, Inc. Completes Formation of Engineering Development Team and Provides Project Update
Autonomix Medical, Inc. has successfully completed its engineering development team formation and announced significant advancements in its medical technology. The company appointed Marco Bedoya as Director of Product Development and has secured collaborations with prominent engineering firms to enhance its catheter-based sensing technology. This technology aims to improve pain management by accurately targeting neural signals associated with pain, with clinical trials expected in the first half of 2025. Autonomix positions itself for a critical year ahead, focusing on innovative treatments for conditions like pancreatic cancer pain.
Read more →AMIXAutonomix Medical, Inc. to Present at the Startup Investing Webinar
Autonomix Medical, Inc. will participate in the Startup Investing Webinar on January 11, 2024, alongside other companies. The CEO, Lori Bisson, will discuss the company's innovative catheter-based sensing technology. This technology is designed to detect neural signals and deliver treatments more accurately than existing methods. Autonomix is initially focusing on applications related to pancreatic cancer pain, which represents a critical area of need in medical treatment.
Read more →AMIXAutonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones
Autonomix Medical, Inc. is advancing innovative medical device technologies aimed at revolutionizing the diagnosis and treatment of nervous system disorders. The company has patented a dual-technology approach that facilitates the detection and ablation of neural signals, targeting the pancreatic cancer pain market initially. CEO Lori Bisson highlighted the firm's commitment to improving patient quality of life and outlined several key milestones for 2024, including commencing first-in-human studies. However, the company also acknowledges the speculative nature of investments in its securities and the risks involved.
Read more →AMIXAutonomix Medical, Inc. to Participate in the Virtual Investor Fireside Chat
Autonomix Medical, Inc. will participate in a Virtual Investor Fireside Chat on December 19, 2023, led by CEO Lori Bisson. The discussion will focus on the company's innovative technologies aimed at improving diagnostics and treatment for diseases affecting the peripheral nervous system. Interested parties will have the opportunity to submit questions during the live event. The company’s first-in-class technology platform has the potential to address multiple health conditions, although it carries inherent risks related to investment and development timelines.
Read more →AMIXAutonomix Medical, Inc. to Present at the Virtual Investor Event Titled “A Breakthrough Medical Device for the Diagnosis and Treatment of Diseases of the Nervous System”
Autonomix Medical, Inc. announced its participation in a virtual investor event scheduled for December 11, 2023, where CEO Lori Bisson will discuss the company's innovative technology aimed at diagnosing and treating nervous system diseases. The technology includes a catheter-based microchip sensing array that shows impressive sensitivity in detecting neural signals. Although the company expresses confidence in its potential applications, it also acknowledges the inherent risks and uncertainties tied to the development and commercialization of its platform.
Read more →AMIXAutonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors
Autonomix Medical, Inc. has announced the appointment of Dr. Christopher C. Capelli to its Board of Directors. Dr. Capelli brings extensive experience in medical technology and innovation, being previously involved with Allergan Aesthetics and Soliton, Inc. His addition is viewed as a significant step forward as Autonomix aims to enhance its technology for diagnosing diseases of the peripheral nervous system. The company is particularly focusing on applications for pancreatic cancer pain and other related conditions.
Read more →AMIXAutonomix Medical, Inc. Launches Social Media Channels
Autonomix Medical, Inc. has announced the launch of its corporate social media channels to keep stakeholders informed about its developments. The company is advancing a dual-purpose technology aimed at detecting and ablating neural signals associated with pain and disease. Currently, it is making strides towards its first-in-human clinical trial targeting pancreatic cancer and pancreatitis pain, scheduled for 2024. The approach promises to provide targeted treatments not previously available, positioning Autonomix at the forefront of innovation in neuromodulation.
Read more →Competitive Position
How AMIX ranks across every disease it competes inCompetitive Position is a premium feature
See how AMIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial